PharmExec

Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial

Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pharm Exec

Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion

Two deals announced this week show established drugmakers adding specialty assets in very different corners of medicine. BioMarin paid $70 million upfront for exclusive worldwide rights to an ...
PharmExec

FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy ...
PharmExec

Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year ...
PharmExec

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals ...